Contraception is central to reproductive autonomy and maternal health equity. The expanding landscape, from short-acting hormonal options to long-acting reversible contraception (LARC), demands evidence-based, person-centered counseling aligned with clinical circumstances, preferences, and life stage.
A 3-year prospective cohort of 4,275 contraceptive users showed that removing access barriers and person-centered counseling yielded low failure rates: 0.7–0.8 per 100 person-years for hormonal IUDs and implants versus 1.6 for pills and 2.6 for condoms, substantially below historical typical-use estimates, suggesting counseling quality and access removal meaningfully narrow the real-world efficacy gap. The 2024 U.S. CDC Medical Eligibility Criteria updates guidance for patients with chronic kidney disease, thrombophilia, peripartum cardiomyopathy, and systemic lupus erythematosus, incorporating new formulations including updated progestin-only pills and levonorgestrel intrauterine systems.
Obstetricians, gynecologists, family medicine physicians, and primary care providers will benefit from peer discussion of method-specific effectiveness data, updated eligibility guidance, and person-centered counseling strategies across diverse patient populations.
How do you incorporate 2024 U.S. Medical Eligibility Criteria updates into contraceptive counseling for patients with complex medical conditions, and what factors most influence your method recommendations? What strategies do you employ to address access barriers and support person-centered contraceptive decision-making, particularly for adolescents, postpartum patients, or those transitioning between methods?
Clearly if the classification is MEC 1, then there is no restriction, and the patient's preference for type of contraception is the most important factor.
If a patient opts for a method that is MEC 2; if there is a MEC 1 level option, we discuss why that method may be a better option. If the patient still opts for the MEC 2 level option after fully informed consent, then we will go with the patient's preference
We do not support the prescribing of MEC 4 options.
MEC 3 level options may be offered in special situations
Teens are able to make decisions regarding their reproductive choice; we do not change our approach to teens (as compared to adults)
Postpartum patient contraception is discussed during the prenatal care - so that immediate transition to PP contraception can occur.
For those transitioning between methods, The US MEC clearly outlines how to safely switch methods - either overlapping, using 7 days of back up (depending on timing) and ensuring that the patient is not pregnant.
We have a high rate of patients that choose LARCs
The ACA has been a big plus for contraceptive choice for patients.